Original Communication| Volume 149, ISSUE 3, P425-432, March 2011

Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas

Published:November 01, 2010DOI:


      The overall survival for neuroblastoma remains dismal, in part due to the emergence of resistance to chemotherapeutic drugs. We have demonstrated that gastrin-releasing peptide (GRP), a gut peptide secreted by neuroblastoma, acts as an autocrine growth factor. We hypothesized that knockdown of GRP will induce apoptosis in neuroblastoma cells and potentiate the cytotoxic effects of chemotherapeutic agents.


      The human neuroblastoma cell lines (JF, SK-N-SH) were transfected with small interfering (si) RNA targeted at GRP. Apoptosis was assessed by DNA fragmentation assay. Immunoblotting was used to confirm molecular markers of apoptosis, and flow cytometry was performed to determine cell cycle arrest after GRP knockdown.


      siGRP resulted in an increase in apoptosis in the absence of chemotherapeutic interventions. A combination of GRP silencing and chemotherapeutic drugs resulted in enhanced apoptosis when compared to either of the treatments alone. GRP silencing led to increased expression of proapoptotic proteins, p53 and p21.


      Silencing of GRP induces apoptosis in neuroblastoma cells; it acts synergistically with chemotherapeutic effects of etoposide and vincristine. GRP knockdown-mediated apoptosis appears to be associated with upregulation of p53 in neuroblastoma cells. Targeting GRP may be postulated as a potential novel agent for combinational treatment to treat aggressive neuroblastomas.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chesler L.
        • Goldenberg D.D.
        • Collins R.
        • Grimmer M.
        • Kim G.E.
        • Tihan T.
        • et al.
        Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
        Neoplasia. 2008; 10: 1268-1274
        • Michaelis M.
        • Klassert D.
        • Barth S.
        • Suhan T.
        • Breitling R.
        • Mayer B.
        • et al.
        Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.
        Mol Cancer. 2009; 8: 80
        • Fan M.
        • Goodwin M.
        • Vu T.
        • Brantley-Finley C.
        • Gaarde W.A.
        • Chambers T.C.
        Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade.
        J Biol Chem. 2000; 275: 29980-29985
        • Gomber S.
        • Dewan P.
        • Chhonker D.
        Vincristine induced neurotoxicity in cancer patients.
        Indian J Pediatr. 2010; 77: 97-100
        • Day T.W.
        • Wu C.H.
        • Safa A.R.
        Etoposide induces protein kinase Cdelta- and caspase-3-dependent apoptosis in neuroblastoma cancer cells.
        Mol Pharmacol. 2009; 76: 632-640
        • Patel O.
        • Shulkes A.
        • Baldwin G.S.
        Gastrin-releasing peptide and cancer.
        Biochim Biophys Acta. 2006; 1766: 23-41
        • Kim S.
        • Hu W.
        • Kelly D.R.
        • Hellmich M.R.
        • Evers B.M.
        • Chung D.H.
        Gastrin-releasing peptide is a growth factor for human neuroblastomas.
        Ann Surg. 2002; 235: 621-629
        • Ishola T.A.
        • Kang J.
        • Qiao J.
        • Evers B.M.
        • Chung D.H.
        Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.
        Biochim Biophys Acta. 2007; 1770: 927-932
        • Qin Y.
        • Halmos G.
        • Cai R.Z.
        • Szoke B.
        • Ertl T.
        • Schally A.V.
        Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
        J Cancer Res Clin Oncol. 1994; 120: 519-528
        • Kang J.
        • Ishola T.A.
        • Baregamian N.
        • Mourot J.M.
        • Rychahou P.G.
        • Evers B.M.
        • et al.
        Bombesin induces angiogenesis and neuroblastoma growth.
        Cancer Lett. 2007; 253: 273-281
        • Zhou J.
        • Chen J.
        • Zhong R.
        • Mokotoff M.
        • Shultz L.D.
        • Ball E.D.
        Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
        Clin Cancer Res. 2006; 12: 2224-2231
        • Stangelberger A.
        • Schally A.V.
        • Letsch M.
        • Szepeshazi K.
        • Nagy A.
        • Halmos G.
        • et al.
        Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
        Int J Cancer. 2006; 118: 222-229
        • Zhou J.
        • Chen J.
        • Mokotoff M.
        • Zhong R.
        • Shultz L.D.
        • Ball E.D.
        Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
        Clin Cancer Res. 2003; 9: 4953-4960
        • Kang J.H.
        • Rychahou P.G.
        • Ishola T.A.
        • Qiao J.
        • Evers B.M.
        • Chung D.H.
        MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
        Biochem Biophys Res Commun. 2006; 351: 192-197
        • Brantley-Finley C.
        • Lyle C.S.
        • Du L.
        • Goodwin M.E.
        • Hall T.
        • Szwedo D.
        • et al.
        The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.
        Biochem Pharmacol. 2003; 66: 459-469
        • Rozengurt E.
        • Sinnett-Smith J.
        Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells.
        Proc Natl Acad Sci U S A. 1983; 80: 2936-2940
        • Alexander R.W.
        • Upp Jr., J.R.
        • Poston G.J.
        • Gupta V.
        • Townsend Jr., C.M.
        • Thompson J.C.
        Effects of bombesin on growth of human small cell lung carcinoma in vivo.
        Cancer Res. 1988; 48: 1439-1441
        • Qiao J.
        • Kang J.
        • Cree J.
        • Evers B.M.
        • Chung D.H.
        Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuroblastomas.
        Ann Surg. 2005; 241: 684-691
        • Szepeshazi K.
        • Schally A.V.
        • Nagy A.
        • Halmos G.
        Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
        Pancreas. 2005; 31: 275-282
        • Kanashiro C.A.
        • Schally A.V.
        • Zarandi M.
        • Hammann B.D.
        • Varga J.L.
        Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
        Int J Oncol. 2007; 30: 1019-1028
        • Zhang Q.
        • Bhola N.E.
        • Lui V.W.
        • Siwak D.R.
        • Thomas S.M.
        • Gubish C.T.
        • et al.
        Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
        Mol Cancer Ther. 2007; 6: 1414-1424
        • Antonoff M.B.
        • Chugh R.
        • Borja-Cacho D.
        • Dudeja V.
        • Clawson K.A.
        • Skube S.J.
        • et al.
        Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo.
        Surgery. 2009; 146: 282-290
        • Teitz T.
        • Wei T.
        • Valentine M.B.
        • Vanin E.F.
        • Grenet J.
        • Valentine V.A.
        • et al.
        Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.
        Nat Med. 2000; 6: 529-535
        • McKenzie P.P.
        • Guichard S.M.
        • Middlemas D.S.
        • Ashmun R.A.
        • Danks M.K.
        • Harris L.C.
        Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated.
        Clin Cancer Res. 1999; 5: 4199-4207
        • Moll U.M.
        • Ostermeyer A.G.
        • Haladay R.
        • Winkfield B.
        • Frazier M.
        • Zambetti G.
        Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage.
        Mol Cell Biol. 1996; 16: 1126-1137
        • McKenzie P.P.
        • Danks M.K.
        • Kriwacki R.W.
        • Harris L.C.
        P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest.
        Cancer Res. 2003; 63: 3840-3844